Multiparticulate L-menthol enteric coating for IBS
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current enteric-coated single-unit peppermint oil capsules for treating gastrointestinal disorders face issues such as premature release in the stomach, erratic gastric emptying, high local exposure leading to symptom aggravation, and the need for frequent dosing due to limited systemic exposure of L-menthol, which is exacerbated by the use of cooking oils that can irritate the stomach and vary in absorption.
Innovation Solution
A multiparticulate formulation with high-purity L-menthol enteric-coated cores, coated with a proteinaceous subcoating and an enteric coating that dissolves at intestinal pH, allowing controlled release over 8 hours, and optionally including terpenes, antioxidants, and green tea extract, to ensure consistent delivery and minimize stomach irritation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If single-unit enteric-coated peppermint oil capsules are used, then the oil is delayed release until intestines, but premature release in stomach occurs causing heartburn
Solution Approach 1:
The patent divides the single-unit capsule into multiple smaller enteric-coated particles or beads. Each particle is individually coated with enteric polymer, ensuring that the collective formulation maintains reliable delayed release while reducing the risk of premature release. The segmented structure allows better distribution and reduces mucoadhesive attachment to esophagus and stomach wall.
Solution Approach 2:
The patent modifies the physical parameters of the peppermint oil delivery system by changing from a single large capsule to multiple small particles with controlled size distribution. The enteric coating thickness and composition are also adjusted to optimize the pH-dependent release profile, ensuring release occurs at intestinal pH (6.8-7.4) rather than stomach pH (1.5-3.5).
2Reliability
If single-unit enteric capsules are used, then enteric coat delays release, but capsule may not pass through pylorus until inter-digestive phase
Solution Approach 1:
The single-unit capsule is segmented into multiple small particles that can pass through the pyloric sphincter more easily. The reduced particle size allows passage during normal digestive phases rather than waiting for the inter-digestive phase, significantly reducing gastric retention time while maintaining enteric coating integrity.
Solution Approach 2:
The patent creates a dynamic particle size distribution where particles are small enough to pass through the pylorus during active digestion but large enough to maintain coating integrity. The multiparticulate formulation adapts to gastric motility patterns, allowing timely passage when the pylorus is open.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The multiparticulate formulation provides reliable and sustained release of L-menthol to the intestines, reducing the frequency of dosing and minimizing stomach irritation, achieving effective symptom relief for gastrointestinal disorders like IBS, FD, and inflammatory bowel disease with improved bioavailability and stability.
Implementation Method 1
an enteric coating that dissolves at intestinal pH
Implementation Method 2
coated with a proteinaceous subcoating and an enteric coating
Data Source
AI summary
A pharmaceutical dosage form includes an effective amount of L-menthol for treating a gastrointestinal disorder. The L-menthol is within a plurality of particulates having a core including crystalline L-menthol dissolved in a terpene-based essential oil. A proteinaceous coating of a continuous film of proteinaceous material is over the core.